Maraviroc

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Kaposi's Sarcoma

Conditions

Kaposi's Sarcoma

Trial Timeline

Mar 9, 2011 → Apr 30, 2015

NCT ID

NCT01276236

About Maraviroc

Maraviroc is a phase 2 stage product being developed by Pfizer for Kaposi's Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01276236. Target conditions include Kaposi's Sarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02934022	Pre-clinical	Completed	Jun 1, 2012	Dec 1, 2014	HIV Infection
NCT01384682	Approved	Completed	Aug 1, 2011	Dec 1, 2015	HIV
NCT01276236	Phase 2	Completed	Mar 9, 2011	Apr 30, 2015	Kaposi's Sarcoma
NCT01133210	Phase 1	Completed	Jan 1, 2011	Nov 1, 2012	Hypertriglyceridemia
NCT00944541	Phase 2	Completed	Sep 1, 2009	Jan 1, 2011	HIV Infection
NCT00982878	Phase 1	Completed	Sep 1, 2009	Feb 1, 2011	HIV Infections
NCT00801515	Pre-clinical	Completed	Aug 1, 2009	Jul 1, 2011	HIV
NCT00850395	Pre-clinical	Completed	Jul 1, 2009	Oct 1, 2011	HIV-1
NCT00791700	Phase 2	UNKNOWN	Apr 22, 2009	Jun 30, 2023	Human Immunodeficiency Virus
NCT00925756	Approved	Completed	Oct 20, 2008	Apr 11, 2014	HIV Infections
NCT00719823	Phase 3	Withdrawn	Aug 1, 2008	May 1, 2010	Human Immunodeficiency Virus Type 1
NCT00775294	Phase 1	Completed	May 1, 2008	Mar 1, 2010	HIV/AIDS
NCT00795444	Phase 2	Completed	Mar 1, 2008	Jan 1, 2015	HIV-1
NCT00703586	Phase 1	Completed	Sep 1, 2007	May 1, 2011	HIV Infections
NCT00478231	Phase 3	Completed	Jul 1, 2007	Sep 1, 2010	Acquired Immunodeficiency Syndrome
NCT00496782	Phase 1	Terminated	Jul 1, 2007	Oct 1, 2008	HIV Infections

Competing Products

5 competing products in Kaposi's Sarcoma

See all competitors

Product	Company	Stage	Hype Score
Selumetinib	AstraZeneca	Phase 1/2	41
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir	Merck	Approved	85
50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin	ImmunityBio	Phase 2	49
VEGF inhibitor PTC299	PTC Therapeutics	Phase 1/2	38
Tc 99m tilmanocept	Navidea Biopharmaceuticals	Phase 2	44

Other Products from Pfizer